Management of inflammaging in kidney diseases: focusing on the current investigational drugs.
Abstract
To improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting specific pathways involved in inflammaging with potential drugs.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper addresses the management of inflammaging in kidney diseases, which is relevant to longevity research as it explores the potential to slow disease progression and enhance longevity by targeting underlying mechanisms of aging. However, the focus on investigational drugs suggests a more symptomatic approach rather than a fundamental solution to the root causes of aging, limiting its overall impact.
Author of this paper? Send a correction.